State of Wisconsin Investment Board increased its position in shares of NxStage Medical, Inc. (NASDAQ:NXTM) by 117.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,056,447 shares of the medical device company’s stock after purchasing an additional 570,847 shares during the period. State of Wisconsin Investment Board owned approximately 1.60% of NxStage Medical worth $25,598,000 at the end of the most recent quarter.
Other hedge funds have also recently added to or reduced their stakes in the company. Public Employees Retirement Association of Colorado purchased a new position in shares of NxStage Medical during the 4th quarter worth about $128,000. Prudential Financial Inc. purchased a new position in shares of NxStage Medical during the 3rd quarter worth about $202,000. Athos Capital Ltd purchased a new position in shares of NxStage Medical during the 3rd quarter worth about $557,000. Aperio Group LLC boosted its stake in shares of NxStage Medical by 36.8% during the 3rd quarter. Aperio Group LLC now owns 11,123 shares of the medical device company’s stock worth $307,000 after purchasing an additional 2,990 shares during the period. Finally, FNY Partners Fund LP bought a new stake in NxStage Medical during the 4th quarter valued at about $300,000. 83.23% of the stock is owned by hedge funds and other institutional investors.
A number of brokerages recently weighed in on NXTM. Zacks Investment Research lowered shares of NxStage Medical from a “hold” rating to a “sell” rating in a report on Tuesday, February 13th. BidaskClub lowered shares of NxStage Medical from a “sell” rating to a “strong sell” rating in a report on Thursday, February 15th. Northland Securities restated a “hold” rating and issued a $30.00 price target on shares of NxStage Medical in a report on Wednesday, November 8th. Finally, ValuEngine lowered shares of NxStage Medical from a “hold” rating to a “sell” rating in a report on Friday, February 2nd. Three analysts have rated the stock with a sell rating and eight have assigned a hold rating to the stock. NxStage Medical presently has a consensus rating of “Hold” and a consensus target price of $30.25.
In other NxStage Medical news, SVP Winifred L. Swan sold 3,500 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $24.88, for a total transaction of $87,080.00. Following the sale, the senior vice president now owns 13,770 shares of the company’s stock, valued at approximately $342,597.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 4.70% of the stock is currently owned by insiders.
NxStage Medical, Inc. (NASDAQ NXTM) opened at $24.62 on Tuesday. The company has a market cap of $1,632.81, a P/E ratio of -351.71 and a beta of -0.08. NxStage Medical, Inc. has a 52 week low of $20.45 and a 52 week high of $30.80.
ILLEGAL ACTIVITY NOTICE: “State of Wisconsin Investment Board Acquires 570,847 Shares of NxStage Medical, Inc. (NXTM)” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/20/state-of-wisconsin-investment-board-acquires-570847-shares-of-nxstage-medical-inc-nxtm.html.
About NxStage Medical
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
Want to see what other hedge funds are holding NXTM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NxStage Medical, Inc. (NASDAQ:NXTM).
Receive News & Ratings for NxStage Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical and related companies with MarketBeat.com's FREE daily email newsletter.